Tag Archives: Joseph Pantginis

H.C. Wainwright Reaffirms Their Buy Rating on Aravive (ARAV)

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Aravive (ARAV – Research Report) yesterday and set a price target of $25.00. The company’s shares closed last Monday at $9.45. According to TipRanks.com, Pantginis is a 5-star analyst with

Mustang Bio (MBIO) Gets a Buy Rating from H.C. Wainwright

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Mustang Bio (MBIO – Research Report), with a price target of $7.00. The company’s shares closed last Monday at $3.73, close to its 52-week low

H.C. Wainwright Keeps Their Buy Rating on Lineage Cell Therapeutics (LCTX)

In a report issued on February 6, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Lineage Cell Therapeutics (LCTX – Research Report), with a price target of $4.00. The company’s shares closed last Monday at $1.25. According to

Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Seattle Genetics (SGEN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cytokinetics (CYTK – Research Report), Seattle Genetics (SGEN – Research Report) and Collegium Pharmaceutical (COLL – Research Report) with bullish sentiments. Cytokinetics

Armata Pharmaceuticals (ARMP) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Armata Pharmaceuticals (ARMP – Research Report) today and set a price target of $9.50. The company’s shares closed last Monday at $4.85. According to TipRanks.com, Pantginis is a 5-star analyst

Pieris Pharmaceuticals (PIRS) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Pieris Pharmaceuticals (PIRS – Research Report) today and set a price target of $9.00. The company’s shares closed last Monday at $2.94, close to its 52-week low of $2.44. According